140894-62-8

Basic information

• Product Name: N^α-Boc-N^ω-tosylarginine N,O-dimethylamide
• Synonyms: N^α-Boc-N^ω-tosylarginine N,O-dimethylamide
• CAS NO: 140894-62-8
• Molecular Weight: 471.578
• Mol File: 140894-62-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N^α-Boc-N^ω-tosylarginine N,O-dimethylamide(CAS DataBase Reference)
• NIST Chemistry Reference: N^α-Boc-N^ω-tosylarginine N,O-dimethylamide(140894-62-8)
• EPA Substance Registry System: N^α-Boc-N^ω-tosylarginine N,O-dimethylamide(140894-62-8)

Safety Data

• Hazardous Substances Data: 140894-62-8(Hazardous Substances Data)

Upstream product

• 13836-37-8 Boc-Arg(Tos)-OH 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 179746-75-9 C₂₆H₃₁N₅O₇S₂ 
• 179746-22-6 C₂₅H₃₁N₅O₅S₂ 
• 186303-91-3 Boc-NH-Arg(Tos)-thiazole 
• 142947-86-2 8-(N-Boc-amino)-11-(3-tosylguanidino)-1-undecen-7-one 
• 142947-85-1 7-(N-Boc-amino)-10-(3-tosylguanidino)-1-decen-6-one 
• 142947-84-0 6-(N-Boc-amino)-9-(3-tosylguanidino)-1-nonen-5-one 
• 287182-89-2 (2S,4R)-1-acetyl-N-[(1S)-1-(2-benzothiazolylhydroxymethyl)-4-[[imino[[(4-methylphenyl)sulfonyl]amino]methyl]amino]butyl]-4-(phenylmethoxy)-2-pyrrolidinecarboxamide 

Relevant articles and documents

Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors

A series of novel transition state factor Xa inhibitors containing a variety of lactam ring systems as central templates was synthesized in an expedient manner and allowed for a great deal of structural variability. Among them, the piperazinone-based inhibitors were found to be not only active against factor Xa but also selective over thrombin. Optimization of the P4 moiety yielded several potent compounds with IC50 below 1 nM against factor Xa.

Selective factor Xa inhibitors

Novel compounds of formula I: including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The co

Synthesis of a homologous series of ketomethylene arginyl pseudodipeptides and application to low molecular weight hirudin-like thrombin inhibitors

The design of low molecular weight thrombin inhibitors IIa-d (hirutonins) that bind concurrently with the enzyme's catalytic site and auxiliary 'anion- binding exosite' for fibrinogen recognition is reported. A practical synthesis of the required homologo